SIGLEC1 and SIGLEC7 expression in circulating monocytes of patients with multiple sclerosis
- 29 August 2012
- journal article
- research article
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 19 (5) , 524-531
Abstract
Sialic acid binding immunoglobulin-like lectins (Siglecs) are cell surface receptors that recognize sialic acids and may attenuate immune responses and reduce inflammation. The purpose of this study was to investigate the role of two members of the Siglec family, SIGLEC1 and SIGLEC7, in the clinical course and disease activity of patients with multiple sclerosis (MS). SIGLEC1 and SIGLEC7 expression was determined by flow cytometry in the blood monocytes of 16 healthy controls and 55 untreated MS patients (13 primary progressive MS (PPMS) patients, 13 secondary progressive MS (SPMS) patients and 29 relapsing–remitting MS (RRMS) patients (18 during clinical remission and 11 during relapse)). SIGLEC1 expression by CD14+ monocytes was significantly increased in MS patients compared with controls (p=0.025 for percentage of positive cells; p=0.007 for mean fluorescence intensity (MFI)). Stratification of patients into different clinical forms revealed increased SIGLEC1 expression in patients with progressive forms of the disease, particularly in those with PPMS (p=0.003 for percentage of positive cells and p=0.001 for MFI when compared with controls; p=0.031 for percentage of positive cells when compared with RRMS patients). Both inflammatory and resident monocytes contributed to the increase in SIGLEC1 expression observed in PPMS patients. SIGLEC7 expression was significantly up-regulated in blood monocytes from RRMS during relapse compared with patients during clinical remission (p=0.001 for MFI). These findings suggest roles for SIGLEC1 in the chronic progressive phases of MS and for SIGLEC7 in acute disease activity.Keywords
This publication has 16 references indexed in Scilit:
- Search for Specific Biomarkers of IFNβ Bioactivity in Patients with Multiple SclerosisPLOS ONE, 2011
- Increased Siglec-1 Expression in Monocytes of Patients with Primary Biliary CirrhosisImmunological Investigations, 2010
- SOCS1 and SOCS3 in the control of CNS immunityTrends in Immunology, 2009
- Sialic acid–binding Ig‐like lectin 1 expression in inflammatory and resident monocytes is a potential biomarker for monitoring disease activity and success of therapy in systemic lupus erythematosusArthritis & Rheumatism, 2008
- A macrophage marker, siglec‐1, is increased on circulating monocytes in patients with systemic sclerosis and induced by type i interferons and toll‐like receptor agonistsArthritis & Rheumatism, 2007
- SOCS3 Targets Siglec 7 for Proteasomal Degradation and Blocks Siglec 7-mediated ResponsesJournal of Biological Chemistry, 2007
- Siglecs—the major subfamily of I-type lectinsGlycobiology, 2005
- Crystal Structure of the N-Terminal Domain of Sialoadhesin in Complex with 3′ Sialyllactose at 1.85 Å ResolutionMolecular Cell, 1998
- GLYCO-FORUM SECTIONGlycobiology, 1998
- Defining the clinical course of multiple sclerosisNeurology, 1996